William Fodor
Chief Tech/Sci/R&D Officer chez HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC.
Fortune : - $ au 31/03/2024
Profil
William Fodor is the Chief Scientific Officer at Harvard Apparatus Regenerative Technology, Inc. He was previously the Chief Executive Officer at GlyGenix Therapeutics, Inc. and a Senior Director at Alexion Pharmaceuticals, Inc. He also held positions as a Senior Director at ViaCell, Inc. and an Associate Professor at the University of Connecticut.
Fodor earned a doctorate degree from The Ohio State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/05/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de William Fodor
| Sociétés | Poste | Début |
|---|---|---|
| HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC. | Chief Tech/Sci/R&D Officer | 01/07/2017 |
Anciens postes connus de William Fodor
| Sociétés | Poste | Fin |
|---|---|---|
ViaCell, Inc.
 ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/07/2008 |
| University of Connecticut | Corporate Officer/Principal | 01/12/2005 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
GlyGenix Therapeutics, Inc.
 GlyGenix Therapeutics, Inc. BiotechnologyHealth Technology GlyGenix Therapeutics, Inc. focuses on treating and curing Glycogen storage diseases. The firm’s services include development of nucleic acid molecules that compensate or correct the genetic defects that cause Glycogen storage disease type 1a. The company was founded by David Feldman and Peter Kaufman in 2006 and is headquartered in Woodbridge, CT. | Chief Executive Officer | - |
Formation de William Fodor
| The Ohio State University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Health Technology |
GlyGenix Therapeutics, Inc.
GlyGenix Therapeutics, Inc. BiotechnologyHealth Technology GlyGenix Therapeutics, Inc. focuses on treating and curing Glycogen storage diseases. The firm’s services include development of nucleic acid molecules that compensate or correct the genetic defects that cause Glycogen storage disease type 1a. The company was founded by David Feldman and Peter Kaufman in 2006 and is headquartered in Woodbridge, CT. | Health Technology |
